John A. Ridge
YOU?
Author Swipe
View article: Phase <scp>II</scp> Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase <span>II</span> Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Open
Prognosis for patients with recurrent/metastatic (R/M) head and neck squamous cell cancer (HNSCC) remains poor. We hypothesized that the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to standard the…
View article: Phase II trial of chemotherapy, cetuximab and erlotinib in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
Phase II trial of chemotherapy, cetuximab and erlotinib in patients with metastatic or recurrent squamous cell carcinoma of the head and neck Open
Prognosis for patients with recurrent/metastatic (R/M) head and neck squamous cell cancer (HNSCC) remains poor. We hypothesized that the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to standard the…
View article: Timing of postoperative radiation therapy for major salivary gland cancers
Timing of postoperative radiation therapy for major salivary gland cancers Open
Background The impact of timing of PORT initiation for major salivary gland cancers on survival is unknown. We aim to examine the impact of PORT timeliness on overall survival (OS) of patients with major salivary gland cancers. Methods Thi…
View article: Supplementary Figure S5 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Figure S5 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
(A and B) KM survival curves specimens with (A) high EGFR stratified by wild type (WT) or amplified (AMP) CCND1, or cases with (B) low EGFR stratified by p16 mRNA expression (TCGA cohort), (C) correlation between medium CDK6 (M) or high CD…
View article: Supplementary Figure S4 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Figure S4 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
(A) Kaplan-Meier survival curves stratified by the expression of the indicated marker (patients treated with surgery only and patients treated with surgery and radiation therapy were included) and multivariate analysis for each marker. Kap…
View article: Data from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Data from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
Clinical decision making for human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is predominantly guided by disease stage and anatomic location, with few validated biomarkers. The epidermal growth factor recep…
View article: Supplemental Tables and Figure Legends from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplemental Tables and Figure Legends from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
Supplementary Table S1 (Excel file). TCGA datasets; Supplementary Table S2. CART cutoff points for each marker and the number of samples (N) in each category; Supplementary Table S3. Adjusted survival analysis; Supplementary Table S4. TCGA…
View article: Supplementary Figure S2 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Figure S2 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
Correlation between marker expression intensity and sample collection year. Corr. = correlation coefficient, A.U. = arbitrary unites.
View article: Data from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Data from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
Clinical decision making for human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is predominantly guided by disease stage and anatomic location, with few validated biomarkers. The epidermal growth factor recep…
View article: Supplementary Figure S2 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Figure S2 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
Correlation between marker expression intensity and sample collection year. Corr. = correlation coefficient, A.U. = arbitrary unites.
View article: Supplementary Figure S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Figure S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
(A) Western blots for the indicated protein markers after siRNA depletion, (B) representative high and low staining immunofluorescent microscopy images for each marker. CK = cytokeratin (epithelial tumor stain), DNA = DAPI stain, C = contr…
View article: Supplementary Figure S5 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Figure S5 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
(A and B) KM survival curves specimens with (A) high EGFR stratified by wild type (WT) or amplified (AMP) CCND1, or cases with (B) low EGFR stratified by p16 mRNA expression (TCGA cohort), (C) correlation between medium CDK6 (M) or high CD…
View article: Supplementary Figure S4 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Figure S4 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
(A) Kaplan-Meier survival curves stratified by the expression of the indicated marker (patients treated with surgery only and patients treated with surgery and radiation therapy were included) and multivariate analysis for each marker. Kap…
View article: Supplementary Table S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Table S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
TCGA datasets.
View article: Supplementary Figure S3 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Figure S3 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
Kaplan-Meier survival curves for T1/2 and T3/4 tumors stratified by the expression of (A) EGFR and (B) HER2. Based on AQUA-expression scores.
View article: Supplementary Figure S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Figure S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
(A) Western blots for the indicated protein markers after siRNA depletion, (B) representative high and low staining immunofluorescent microscopy images for each marker. CK = cytokeratin (epithelial tumor stain), DNA = DAPI stain, C = contr…
View article: Supplementary Figure S3 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Figure S3 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
Kaplan-Meier survival curves for T1/2 and T3/4 tumors stratified by the expression of (A) EGFR and (B) HER2. Based on AQUA-expression scores.
View article: Supplemental Tables and Figure Legends from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplemental Tables and Figure Legends from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
Supplementary Table S1 (Excel file). TCGA datasets; Supplementary Table S2. CART cutoff points for each marker and the number of samples (N) in each category; Supplementary Table S3. Adjusted survival analysis; Supplementary Table S4. TCGA…
View article: Supplementary Table S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Supplementary Table S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer Open
TCGA datasets.
View article: Supplementary Figure Legend from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Supplementary Figure Legend from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers Open
PDF file - 56K
View article: Data Supplement from Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303
Data Supplement from Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303 Open
List of Supplemental Materials: Supplemental Table 1. Criteria for Unresectable Disease Supplemental Table 2. Modified RECIST Criteria for Head and Neck Cancer. Supplemental Table 3. Summary of Serum Analyte Levels. Supplemental Figure 1. …
View article: Data from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Data from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers Open
Purpose: Multimodality treatment of squamous cell carcinoma of the head and neck (SCCHN) often involves radiotherapy and cisplatin-based therapy. Elevated activity of DNA repair mechanisms, such as the nucleotide excision repair (NER) path…
View article: Supplementary Table 1 from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Supplementary Table 1 from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers Open
PDF file - 78K, Characteristics of recurrent cases.
View article: Data from Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer
Data from Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer Open
Purpose:Previous studies indicate that the benefit of therapy depends on patients' risk for cancer recurrence relative to noncancer mortality (ω ratio). We sought to test the hypothesis that patients with head and neck cancer (HNC) with a …
View article: Supplementary Figures 1 - 2 from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Supplementary Figures 1 - 2 from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers Open
PDF file - 194K, Supplemental Figure S1. A. Immunofluorescence staining: ERCC1 antibody of Sigma HPA029773 (upper row) and Lab Vision 8F1 (middle row) showed clear nuclear staining. Both cytoplasmic and nuclear staining of ERCC1 was seen u…
View article: Supplementary Tables 1 - 3, Figures 1 - 4 from Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303
Supplementary Tables 1 - 3, Figures 1 - 4 from Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303 Open
Supplemental Table 1. Criteria for Unresectable Disease Supplemental Table 2. Modified RECIST Criteria for Head and Neck Cancer. Supplemental Table 3. Summary of Serum Analyte Levels. Supplemental Figure 1. Study Schematic Supplemental Fig…
View article: Supplementary Data from Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer
Supplementary Data from Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer Open
Supplementary Data: Tables S1-S2; Figures S1-S4
View article: Data from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Data from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers Open
Purpose: Multimodality treatment of squamous cell carcinoma of the head and neck (SCCHN) often involves radiotherapy and cisplatin-based therapy. Elevated activity of DNA repair mechanisms, such as the nucleotide excision repair (NER) path…
View article: Supplementary Figure Legend from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Supplementary Figure Legend from Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers Open
PDF file - 56K